Gufic Biosciences Limited has paid a penalty of ₹1.72 lakh (excluding GST) to BSE on March 13, 2026, after the stock exchange rejected the company's waiver application. The penalty relates to alleged non-compliance with SEBI listing regulations regarding the appointment of an independent director.

Regulatory Non-Compliance Details

The penalties stem from the company's appointment of Mr. Kamal Kishore Seth (DIN: 00194986) as an Additional Director (Non-Executive Independent Director) without obtaining shareholders' approval by way of a special resolution. The regulatory issue arose because Mr. Seth had attained the age of seventy-five years, requiring special approval under Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Penalty Payment Timeline

The company had initially paid ₹8,000 (excluding GST) each to both BSE and NSE for the quarter ended June 30, 2024, while filing waiver applications for the penalties.

Waiver Application Outcome

Gufic Biosciences had submitted waiver applications to both stock exchanges seeking relief from the imposed penalties. The company had previously communicated about these penalties through intimations dated August 22, 2024, and November 22, 2024. However, BSE rejected the waiver application, leading to the payment of the September 2024 quarter penalty.

Regulatory Compliance Disclosure

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by informing both BSE and NSE about the penalty payment. Company Secretary and Compliance Officer Ami Shah signed the regulatory filing on March 13, 2026.

The disclosure demonstrates the company's commitment to maintaining transparency with stakeholders regarding regulatory matters and penalty payments to stock exchanges.

Gufic Biosciences Limited has released its comprehensive investor presentation covering unaudited financial results for Q3FY26, following its scheduled earnings conference call on February 16, 2026. The pharmaceutical company shared detailed insights into its quarterly performance and strategic initiatives across multiple business segments.

Q3FY26 Financial Performance

The company reported total revenue of ₹231.10 crore for Q3FY26, representing an increase from ₹207.80 crore in Q3FY25. However, profitability metrics showed some moderation compared to the previous year.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, Gufic Biosciences achieved total revenue of ₹688.40 crore compared to ₹614.80 crore in the corresponding period of the previous year.

Indore Facility Progress Update

The company provided significant updates on its advanced lyophilized injectable facility at Indore, which commenced production in October 2024. The facility is designed to meet WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards with substantial manufacturing capacity.

The facility has achieved 30% capacity utilization for FY26 and is on track for EBITDA breakeven. The company has completed performance qualification for all lines, media fills for sterility validation, and received 203 product permissions from State FDA to date.

Business Platform Performance

Gufic Biosciences operates through multiple specialized platforms including Hospital Injectable Platform focusing on anti-microbials and cardiac critical care, Women's Health Platform covering assisted reproductive technology, and Botulinum Toxin Platform for aesthetics and neurology applications. The company continues to strengthen its presence in critical care divisions and infertility segments while expanding its international business footprint.

Regulatory and Compliance Updates

The investor presentation was formally communicated to BSE Limited and National Stock Exchange of India Limited on February 13, 2026, pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Whole Time Director Pankaj Gandhi signed the official communication to both exchanges, ensuring compliance with regulatory requirements.